期刊文献+

FOXM1与Ki67共表达对三阴性乳腺癌患者预后的影响 被引量:2

Effect of FOXM1 and Ki67 co-expression on prognosis of patients with triple negative breast cancers
原文传递
导出
摘要 目的探讨癌基因叉头框蛋白M1(FOXM1)与增殖细胞Ki67抗原表达对三阴性乳腺癌(TNBC)患者预后的影响。方法免疫组化分析FOXM1和Ki67在60例TNBC组织中的表达,分析其表达量的相关性及其对TNBC患者预后的影响。结果 TNBC组织中FOXM1和Ki67共表达与肿瘤的大小、分化程度、TNM分期、腋窝淋巴结转移和血管神经侵犯密切相关(P<0.05或P<0.01)。FOXM1与Ki67表达呈正相关(r=0.4635,P<0.01)。FOXM1和Ki67高表达以及腋窝淋巴结转移情况可以作为判断TNBC预后的独立因素。结论TNBC组织高表达FOXM1和Ki67,有望成为TNBC患者预后判断的新指标,也为探索TNBC治疗新靶点提供思路。 Objective To investigate the effect of the expressions of forkhead box M1(FOXM1)and nuclear-associated antigen Ki67 on the prognosis of the patients with triple negative breast cancers(TNBC).Methods The expressions of FOXM1 and Ki67in TNBC tissues were detected by immunohistochemistry in 60 TNBC cases.The correlation of FOXM1 and Ki67 expressions and their effect on the prognosis of TNBC patients were analyzed.Results The expressions of FOXM1 and Ki67in TNBC were closely related to tumour size,differentiation,TNM stage,axillary lymph node metastasis,vessel and/or nersis invasion(P〈0.05 or P〈0.01).The expression of FOXM1 was positively correlated with that of Ki67(r=0.4635,P〈0.01).The overexpressions of FOXM1 and Ki67 in TNBC and axillary lymph node metastasis were the independent factors for predicting the prognosis of TNBC patients.Conclusion The expressions of FOXM1 and Ki67in TNBC are higher,which could become the indicators for the prediction of the prognosis and new clue of exploring new therapeutic target for TNBC.
出处 《江苏医药》 CAS 2015年第20期2391-2393,F0003,共4页 Jiangsu Medical Journal
基金 江苏省南通市青年基金(WQ2015047)
关键词 三阴性乳腺癌 叉头框蛋白M1 KI67 Triple negative breast cancers Forkhead box M1 Ki67
  • 相关文献

参考文献3

二级参考文献50

  • 1李传芬,荆文,杜会芹,陈苏,张会亮,李云龙.调控胞质分裂的中心体相关蛋白Cep55[J].生命的化学,2006,26(6):487-490. 被引量:2
  • 2Siegel R, Naishadham D, Jemal A. Cancer J Clin, 2013, 63 : 11-30.
  • 3Jemal A, Bray F, Center MM, et al. Cancer J Clin, 2011, 61 : 69-90.
  • 4Cancer statistics, 2013. CA Global cancer statistics. CA Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med, 2010, 363: 1938-1948.
  • 5Constantinidou A, Jones RL, Reis-Filho JS. Beyond triple- negative breast cancer: the need to define new subtypes. Expert Rev Anticancer Ther, 2010, 10 : 1197-1213.
  • 6Park YH, Lee SJ, Cho EY, et al. Clinical relevance of TNM staging system according to breast cancer subtypes. Ann Oncol, 2011, 22: 1554-1560.
  • 7Lin NU, Vanderplas A, Hughes ME, et al. Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Cancer, 2012, 118: 5463-5472.
  • 8Lin NU, Claus E, Sohl J, et at. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer, 2008, 113: 2638-2645.
  • 9Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol, 2011, 22: 1736-1747.
  • 10Yao-Lung K, Dar-Ren C, Tsai-Wang C. Clinicopathologieal features of triple-negative breast cancer in Taiwan Residents women. Int J Clin Oncol, 201!, 16 : 500-505.

共引文献19

同被引文献4

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部